Browse Category

NASDAQ:INBS News 31 December 2025 - 2 January 2026

INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

NEW YORK, Jan 2, 2026, 11:40 ET — Regular session Shares of Intelligent Bio Solutions Inc slid on Friday as investors digested the micro-cap medtech company’s $10 million private placement announced late Wednesday. The stock was down 12.1% at $8.38 by 11:25 a.m. ET. Benzinga The pullback comes after the stock more than doubled on Dec. 31 following news of a manufacturing partnership aimed at scaling production of its fingerprint-based drug screening reader. Nasdaq The timing matters because INBS is trying to ramp production and shore up supply as it targets a 2026 U.S. market entry, while also tapping capital
INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

NEW YORK, January 1, 2026, 03:10 ET — Market closed Intelligent Bio Solutions Inc said late Wednesday it will raise about $10 million in a private placement, sending its shares lower in after-hours trading after a sharp rally earlier in the session. The financing lands as the micro-cap medtech company pitches a faster path to scale for its fingerprint-based drug screening reader, with management pointing to lower production costs and higher profitability ahead of a planned U.S. market entry. Private placements are a common funding route for small companies, but they can dilute existing shareholders — meaning each share represents
INBS stock jumps on Syrma Johari deal: Intelligent Bio Solutions targets 40% cost cuts

INBS stock jumps on Syrma Johari deal: Intelligent Bio Solutions targets 40% cost cuts

NEW YORK, December 31, 2025, 5:04 PM ET — After-hours Shares of Intelligent Bio Solutions Inc more than doubled in Wednesday’s regular session as investors piled into the micro-cap medical technology stock on a fresh manufacturing update. The stock closed at $9.53, up $5.43 from Tuesday’s close of $4.10, and traded at $8.95 in after-hours dealings. The shares ranged from $5.62 to $12.94 on the day, giving the company a market value of about $9 million. Google The rally matters because manufacturing economics are a pressure point for small diagnostics and testing-device makers. Investors want proof that scaling hardware production
INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

NEW YORK, December 31, 2025, 13:04 ET — Regular session Intelligent Bio Solutions Inc shares surged on Wednesday after the company said it struck a new manufacturing partnership aimed at lowering costs for its fingerprint-based drug testing device. The stock was up $6.56, or about 160%, at $10.66 by 1:04 p.m. ET. Google The announcement matters now because Intelligent Bio is trying to improve its unit economics as it scales. The company said the partnership should drive annual production cost savings of more than 40%, translating to an expected improvement of about 20 percentage points in gross margin. Gross margin

Stock Market Today

Amazon stock slides as $200B AI spending plan meets cautious profit outlook

Amazon stock slides as $200B AI spending plan meets cautious profit outlook

7 February 2026
Amazon shares fell 9% Friday after the company announced plans for $200 billion in 2026 capital spending, mainly for AWS and AI, and issued a first-quarter profit outlook below estimates. The stock drop could erase $200 billion in market value. Fourth-quarter net sales rose 14% to $213.4 billion, while free cash flow declined due to higher spending on AI infrastructure.
Blockchain’s New Pitch: Tracking Supply-Chain Emissions for a Price

Blockchain’s New Pitch: Tracking Supply-Chain Emissions for a Price

7 February 2026
Blockchain industry groups are promoting supply-chain emissions tracking and data transparency, not crypto trading, as key business uses. Companies face mounting pressure to map Scope 3 emissions, which are often hard to verify. Past blockchain supply-chain projects, including Maersk’s TradeLens, struggled with adoption when partners failed to participate.
Go toTop